427 related articles for article (PubMed ID: 31308060)
1. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
Lindemann A; Patel AA; Silver NL; Tang L; Liu Z; Wang L; Tanaka N; Rao X; Takahashi H; Maduka NK; Zhao M; Chen TC; Liu W; Gao M; Wang J; Frank SJ; Hittelman WN; Mills GB; Myers JN; Osman AA
Clin Cancer Res; 2019 Sep; 25(18):5650-5662. PubMed ID: 31308060
[TBL] [Abstract][Full Text] [Related]
2. Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk
Tanaka N; Patel AA; Tang L; Silver NL; Lindemann A; Takahashi H; Jaksik R; Rao X; Kalu NN; Chen TC; Wang J; Frederick MJ; Johnson F; Gleber-Netto FO; Fu S; Kimmel M; Wang J; Hittelman WN; Pickering CR; Myers JN; Osman AA
Clin Cancer Res; 2017 Nov; 23(21):6541-6554. PubMed ID: 28790110
[No Abstract] [Full Text] [Related]
3. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.
Osman AA; Monroe MM; Ortega Alves MV; Patel AA; Katsonis P; Fitzgerald AL; Neskey DM; Frederick MJ; Woo SH; Caulin C; Hsu TK; McDonald TO; Kimmel M; Meyn RE; Lichtarge O; Myers JN
Mol Cancer Ther; 2015 Feb; 14(2):608-19. PubMed ID: 25504633
[TBL] [Abstract][Full Text] [Related]
4. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells.
Synnott NC; O'Connell D; Crown J; Duffy MJ
Breast Cancer Res Treat; 2020 Jan; 179(1):47-56. PubMed ID: 31538264
[TBL] [Abstract][Full Text] [Related]
5. COTI-2 induces cell apoptosis in pediatric acute lymphoblastic leukemia via upregulation of miR-203.
Guo Y; Zhu X; Sun X
Bioengineered; 2020 Dec; 11(1):201-208. PubMed ID: 32063077
[TBL] [Abstract][Full Text] [Related]
6. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
[TBL] [Abstract][Full Text] [Related]
7. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
[TBL] [Abstract][Full Text] [Related]
8. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
[TBL] [Abstract][Full Text] [Related]
9. AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway.
Chang WM; Chang YC; Yang YC; Lin SK; Chang PM; Hsiao M
J Exp Clin Cancer Res; 2019 Jun; 38(1):245. PubMed ID: 31182137
[TBL] [Abstract][Full Text] [Related]
10. PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma.
Ganci F; Pulito C; Valsoni S; Sacconi A; Turco C; Vahabi M; Manciocco V; Mazza EMC; Meens J; Karamboulas C; Nichols AC; Covello R; Pellini R; Spriano G; Sanguineti G; Muti P; Bicciato S; Ailles L; Strano S; Fontemaggi G; Blandino G
Clin Cancer Res; 2020 Jun; 26(12):2956-2971. PubMed ID: 31969334
[TBL] [Abstract][Full Text] [Related]
11. Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma.
Di Agostino S; Valenti F; Sacconi A; Fontemaggi G; Pallocca M; Pulito C; Ganci F; Muti P; Strano S; Blandino G
Theranostics; 2018; 8(7):1850-1868. PubMed ID: 29556360
[TBL] [Abstract][Full Text] [Related]
12. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.
Lee JW; Parameswaran J; Sandoval-Schaefer T; Eoh KJ; Yang DH; Zhu F; Mehra R; Sharma R; Gaffney SG; Perry EB; Townsend JP; Serebriiskii IG; Golemis EA; Issaeva N; Yarbrough WG; Koo JS; Burtness B
Clin Cancer Res; 2019 Jun; 25(11):3430-3442. PubMed ID: 30755439
[TBL] [Abstract][Full Text] [Related]
13. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.
Skinner HD; Sandulache VC; Ow TJ; Meyn RE; Yordy JS; Beadle BM; Fitzgerald AL; Giri U; Ang KK; Myers JN
Clin Cancer Res; 2012 Jan; 18(1):290-300. PubMed ID: 22090360
[TBL] [Abstract][Full Text] [Related]
14. p53-independent Noxa induction by cisplatin is regulated by ATF3/ATF4 in head and neck squamous cell carcinoma cells.
Sharma K; Vu TT; Cook W; Naseri M; Zhan K; Nakajima W; Harada H
Mol Oncol; 2018 Jun; 12(6):788-798. PubMed ID: 29352505
[TBL] [Abstract][Full Text] [Related]
15. STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner.
Sun S; Wu Y; Guo W; Yu F; Kong L; Ren Y; Wang Y; Yao X; Jing C; Zhang C; Liu M; Zhang Y; Zhao M; Li Z; Wu C; Qiao Y; Yang J; Wang X; Zhang L; Li M; Zhou X
Clin Cancer Res; 2018 Jun; 24(11):2665-2677. PubMed ID: 29540490
[No Abstract] [Full Text] [Related]
16. Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer.
Friedman J; Nottingham L; Duggal P; Pernas FG; Yan B; Yang XP; Chen Z; Van Waes C
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6568-78. PubMed ID: 18006756
[TBL] [Abstract][Full Text] [Related]
17. Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress.
Lindemann A; Patel AA; Tang L; Tanaka N; Gleber-Netto FO; Bartels MD; Wang L; McGrail DJ; Lin SY; Frank SJ; Frederick MJ; Myers JN; Osman AA
Mol Cancer Ther; 2021 Jul; 20(7):1257-1269. PubMed ID: 33947685
[TBL] [Abstract][Full Text] [Related]
18. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma.
Jin S; Yang X; Li J; Yang W; Ma H; Zhang Z
Mol Cancer; 2019 Mar; 18(1):38. PubMed ID: 30857539
[TBL] [Abstract][Full Text] [Related]
19. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
20. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]